drugset

drugset / Trial / NCT04870866

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

NCT04870866 ↗

Phase 2 Active not recruiting 13 enrolled University Hospital, Akershus Haukeland University Hospital · collab Oslo University Hospital · collab South-Eastern Norway Regional Health Authority · collab St. Olavs Hospital · collab Sykehuset Innlandet HF · collab The Bergesen Foundation · collab University Hospital of North Norway · collab University of Bergen · collab

NaSingle-groupOpen-labelTreatment

Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

Timeline

Start: 2019-06-05
Primary completion: 2024-09-03
Completion: 2027-06-16

Publications

Background Fang EF, Kassahun H, Croteau DL, Scheibye-Knudsen M, Marosi K, Lu H, Shamanna RA, Kalyanasundaram S, Bollineni RC, Wilson MA, Iser WB, Wollman BN, Morevati M, Li J, Kerr JS, Lu Q, Waltz TB, Tian J, Sinclair DA, Mattson MP, Nilsen H, Bohr VA. NAD+ Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. Cell Metab. 2016 Oct 11;24(4):566-581. doi: 10.1016/j.cmet.2016.09.004.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nicotinamide riboside	Small molecule	300 mg	—

Indications